<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAC Antimicrob Resist</journal-id><journal-id journal-id-type="iso-abbrev">JAC Antimicrob Resist</journal-id><journal-id journal-id-type="pmc-domain-id">4039</journal-id><journal-id journal-id-type="pmc-domain">jacamr</journal-id><journal-id journal-id-type="publisher-id">jacamr</journal-id><journal-title-group><journal-title>JAC-Antimicrobial Resistance</journal-title></journal-title-group><issn pub-type="epub">2632-1823</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11836883</article-id><article-id pub-id-type="pmcid-ver">PMC11836883.1</article-id><article-id pub-id-type="pmcaid">11836883</article-id><article-id pub-id-type="pmcaiid">11836883</article-id><article-id pub-id-type="pmid">39973907</article-id><article-id pub-id-type="doi">10.1093/jacamr/dlaf015</article-id><article-id pub-id-type="publisher-id">dlaf015</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00740</subject><subject>AcademicSubjects/SCI01150</subject></subj-group></article-categories><title-group><article-title>Plasma concentration of azithromycin and correlation with clinical outcomes in patients with enteric fever</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bandyopadhyay</surname><given-names initials="R">Rini</given-names></name><aff>
<institution>Department of Infectious Diseases, Christian Medical College</institution>, <addr-line>Vellore, Tamilnadu</addr-line>, <country country="IN">India</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mathew</surname><given-names initials="SK">Sumith K</given-names></name><aff>
<institution>Department of Clinical Pharmacology, Christian Medical College</institution>, <addr-line>Vellore, Tamilnadu</addr-line>, <country country="IN">India</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Veeraraghavan</surname><given-names initials="B">Balaji</given-names></name><aff>
<institution>Department of Clinical Microbiology, Christian Medical College</institution>, <addr-line>Vellore, Tamilnadu</addr-line>, <country country="IN">India</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Samuel</surname><given-names initials="P">Prasanna</given-names></name><aff>
<institution>Department of Biostatistics, Christian Medical College</institution>, <addr-line>Vellore, Tamilnadu</addr-line>, <country country="IN">India</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Backiyaraj</surname><given-names initials="J">Jacob</given-names></name><aff>
<institution>Department of Infectious Diseases, Christian Medical College</institution>, <addr-line>Vellore, Tamilnadu</addr-line>, <country country="IN">India</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sathyendra</surname><given-names initials="S">Sowmya</given-names></name><aff>
<institution>Department of Medicine III, Christian Medical College</institution>, <addr-line>Vellore, Tamilnadu</addr-line>, <country country="IN">India</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5115-067X</contrib-id><name name-style="western"><surname>Rupali</surname><given-names initials="P">Priscilla</given-names></name><aff>
<institution>Department of Infectious Diseases, Christian Medical College</institution>, <addr-line>Vellore, Tamilnadu</addr-line>, <country country="IN">India</country></aff><xref rid="dlaf015-cor1" ref-type="corresp"/></contrib></contrib-group><author-notes><corresp id="dlaf015-cor1">Corresponding author. E-mail: <email>prisci@cmcvellore.ac.in</email></corresp></author-notes><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-02-19"><day>19</day><month>2</month><year>2025</year></pub-date><volume>7</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">477738</issue-id><elocation-id>dlaf015</elocation-id><history><date date-type="received"><day>09</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>19</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-22 23:26:00.927"><day>22</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#8212;for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="dlaf015.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="dlaf015.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Azithromycin is the only oral option available for XDR enteric fever. Studies correlating azithromycin levels with treatment success are rare.</p></sec><sec id="s2"><title>Methods</title><p>Serum azithromycin levels after administration of a once-daily 20&#8197;mg/kg dose for 7&#8197;days were measured in a single-centre prospective cohort of 25 consecutive adults with blood culture-positive enteric fever. Five blood samples were collected on Day 2 after starting azithromycin, i.e. 30&#8197;min before dosing (trough), and 2, 5, 12 and 24&#8197;h after dosing. The MIC was determined for all isolates and azithromycin plasma concentration was determined using LC-MS. Clinical and microbiological outcomes were documented.</p></sec><sec id="s3"><title>Results</title><p>
<italic toggle="yes">Salmonella enterica</italic> serovar Typhi accounted for 92% (<italic toggle="yes">n</italic>&#8202;=&#8202;23) and <italic toggle="yes">Salmonella enterica</italic> serovar Paratyphi 8% (<italic toggle="yes">n</italic>&#8202;=&#8202;2). Ten (40%) patients received IV azithromycin, and the rest received oral therapy. The median (IQR, range) MIC for azithromycin was 4 (4&#8211;6, 3&#8211;12)&#8197;mg/L. Mean azithromycin plasma concentration ranges were: trough, 0.24&#8202;&#177;&#8202;0.19&#8197;mg/L; 2&#8197;h, 1.24&#8202;&#177;&#8202;0.98&#8197;mg/L; 5&#8197;h, 0.64&#8202;&#177;&#8202;0.51&#8197;mg/L; 12&#8197;h, 0.31&#8202;&#177;&#8202;0.16&#8197;mg/L; and 24&#8197;h, 0.37&#8202;&#177;&#8202;0.30&#8197;mg/L. The <italic toggle="yes">C</italic><sub>max</sub>/MIC and AUC/MIC for azithromycin were 0.29&#8202;&#177;&#8202;0.22 and 2.64&#8202;<underline>&#177;</underline>&#8202;1.64, respectively. The median (IQR, range) fever clearance time was 3 (2&#8211;3, 2&#8211;5)&#8197;days and the length of hospital stay was 7 (5.5&#8211;12, 4&#8211;16)&#8197;days. There was no clinical or microbiological failure, relapse or mortality.</p></sec><sec id="s4"><title>Conclusions</title><p>Azithromycin was effective in treatment of enteric fever, despite low extracellular azithromycin plasma levels.</p></sec></abstract><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Institutional Internal Fluid</institution></institution-wrap></funding-source><award-id>22Q257</award-id></award-group></funding-group><counts><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="dlaf015-s1"><title>Introduction</title><p>Enteric fever remains a major community-acquired bacteraemic illness in tropical low-resource settings. Typhoidal <italic toggle="yes">Salmonella</italic> strains (<italic toggle="yes">Salmonella enterica</italic> serovar Typhi, Paratyphi A, Paratyphi B and Paratyphi C) are human host-restricted organisms causing typhoid fever and paratyphoid fever, collectively referred to as enteric fever. Increased resistance to commonly available oral agents has been reported over the last two decades. With emergence of MDR, defined as resistance to ampicillin, chloramphenicol and co-trimoxazole, and decreased susceptibility to fluoroquinolones, oral drugs available to treat enteric fever are scarce.<sup><xref rid="dlaf015-B1" ref-type="bibr">1</xref></sup> Fluoroquinolones were considered as the most effective treatment for typhoid fever in the 1990s, but emergence of nalidixic acid-resistant <italic toggle="yes">S.</italic> Typhi and microbiological failure to ciprofloxacin has led to decreased treatment options.<sup><xref rid="dlaf015-B2" ref-type="bibr">2</xref>,<xref rid="dlaf015-B3" ref-type="bibr">3</xref></sup></p><p>The WHO recommends ceftriaxone and azithromycin as the drugs of choice in the treatment of invasive <italic toggle="yes">S.</italic> Typhi infection. Although ceftriaxone is commonly used for the treatment of MDR <italic toggle="yes">S.</italic> Typhi infection, the cost, parenteral administration and recently reported ESBL production are major limitations, particularly as most enteric fever patients are treated as outpatients in low- and middle-income countries.<sup><xref rid="dlaf015-B4" ref-type="bibr">4</xref>,<xref rid="dlaf015-B5" ref-type="bibr">5</xref></sup> Hence, azithromycin is increasingly used as a well-tolerated, safe and efficacious oral antibiotic in the treatment of uncomplicated typhoid fever in Southeast Asia.<sup><xref rid="dlaf015-B6" ref-type="bibr">6</xref></sup></p><p>Azithromycin, an azalide macrolide antibiotic, has unique pharmacokinetic and pharmacodynamic (PK/PD) properties compared with other macrolides due to its dibasic structure. It&#160;has time-dependent bacteriostatic or bactericidal activity, along with concentration-dependent bactericidal activity.<sup><xref rid="dlaf015-B7" ref-type="bibr">7</xref></sup> Azithromycin is distributed extensively in various tissues and body fluids with a long serum half-life.<sup><xref rid="dlaf015-B8" ref-type="bibr">8</xref></sup> The drug concentrates in WBCs and the WBC/plasma ratio is high, even at the end of active treatment, resulting in a prolonged post-antibiotic effect.<sup><xref rid="dlaf015-B9" ref-type="bibr">9</xref></sup> Azithromycin achieves more than 100-fold higher concentration in the macrophages and leucocytes when compared with serum, with excellent tissue penetration.<sup><xref rid="dlaf015-B10" ref-type="bibr">10</xref>,<xref rid="dlaf015-B11" ref-type="bibr">11</xref></sup> With <italic toggle="yes">S.</italic> Typhi being a predominantly intracellular organism, using azithromycin, which has suitable pharmacokinetic properties and a high intracellular concentration, makes intuitive sense.</p><p>Consequently, azithromycin achieves a low plasma (extracellular) concentration, secondary to uptake by fibroblasts and cells like polymorphonuclear leucocytes (PMNLs), monocytes and lymphocytes.<sup><xref rid="dlaf015-B8" ref-type="bibr">8</xref></sup> The EUCAST (v 14.0)<sup><xref rid="dlaf015-B12" ref-type="bibr">12</xref></sup> and CLSI 2024 guidelines publish an azithromycin MIC breakpoint of &#8804;16&#8197;mg/L for WT <italic toggle="yes">S.</italic> Typhi isolates, which is extrapolated for use with <italic toggle="yes">S</italic>. Paratyphi isolates.<sup><xref rid="dlaf015-B13" ref-type="bibr">13</xref>,<xref rid="dlaf015-B14" ref-type="bibr">14</xref></sup> However, as the drug concentrates more in tissues and intracellular compartments, the role of the MIC in predicting clinical outcomes becomes questionable. Further, there are concerns that up to one-third of <italic toggle="yes">S.</italic> Typhi may be found in the extracellular compartment and these low levels of azithromycin in plasma may lead to resistance. <italic toggle="yes">Salmonella</italic> isolates with increased azithromycin MICs have been reported from India and in returning travellers.<sup><xref rid="dlaf015-B15" ref-type="bibr">15</xref></sup> Cases with probable azithromycin resistance and clinical failure have also been reported from the Indian subcontinent and South Asia.<sup><xref rid="dlaf015-B16" ref-type="bibr">16&#8211;18</xref></sup> Mechanisms responsible for azithromycin resistance are the presence of resistance genes (<italic toggle="yes">acrB</italic>, <italic toggle="yes">acrR</italic> and <italic toggle="yes">rplV</italic> mutations) or acquisition of macrolide efflux pump genes (<italic toggle="yes">macA</italic> and <italic toggle="yes">macB</italic>).<sup><xref rid="dlaf015-B17" ref-type="bibr">17&#8211;21</xref></sup> In the USA, <italic toggle="yes">mph</italic>(A) and related phosphotransferase genes are the most common cause of azithromycin resistance observed in <italic toggle="yes">S.</italic> Typhi.<sup><xref rid="dlaf015-B22" ref-type="bibr">22</xref></sup> Notably, azithromycin-resistant <italic toggle="yes">S.</italic> Typhi isolates have been found to carry a non-synonymous single-point mutation, R717L/Q, in the <italic toggle="yes">acrB</italic> efflux pump gene, which has been reported in strains from Bangladesh, Pakistan, Nepal and India.<sup><xref rid="dlaf015-B23" ref-type="bibr">23</xref></sup> Presence of efflux pumps might be responsible for the poor clinical outcomes; however, this is not easily picked up via routine antibiotic susceptibility testing or MIC.</p><p>Reports of isolates from enteric fever patients with azithromycin MICs of &gt;16&#8197;mg/L are emerging.<sup><xref rid="dlaf015-B1" ref-type="bibr">1</xref>,<xref rid="dlaf015-B23" ref-type="bibr">23</xref>,<xref rid="dlaf015-B24" ref-type="bibr">24</xref></sup> The PK/PD parameters predictive for the clinical efficacy of azithromycin in enteric fever have not been prospectively studied.<sup><xref rid="dlaf015-B13" ref-type="bibr">13</xref>,<xref rid="dlaf015-B14" ref-type="bibr">14</xref></sup> Moreover, optimal therapeutic extracellular plasma levels of azithromycin that achieve both clinical and microbiological cure remain largely unknown. This pilot study was performed to determine the PK of azithromycin and the role of extracellular plasma levels of azithromycin in predicting clinical and microbiological outcomes in adult patients with uncomplicated enteric fever in South India.</p></sec><sec sec-type="materials|methods" id="dlaf015-s2"><title>Materials and methods</title><p>The study population included a prospective cohort of 25 consecutive adults (&gt;18&#8197;years old) admitted with blood culture-positive enteric fever to a tertiary care hospital in South India between August 2020 and March 2022. The study protocol was approved by the Institutional Review Board and Ethics committee of Christian Medical College, Vellore, India (IRB Min. No. 12777 dated 8 April 2020), and informed consent was obtained from the study participants. Patients unwilling to provide serial plasma samples (<italic toggle="yes">n</italic>&#8202;=&#8202;3) and those on combination therapy (<italic toggle="yes">n</italic>&#8202;=&#8202;2) were excluded. Patients who received initial active therapy other than azithromycin were included in the study, provided it was stopped prior to starting azithromycin monotherapy.</p><p>All 25 patients recruited to the study received the recommended dosing of 20&#8197;mg/kg once daily<sup><xref rid="dlaf015-B25" ref-type="bibr">25</xref></sup> oral or IV azithromycin for treatment of enteric fever for a total duration of 7&#8197;days. The route of drug administration (oral or IV) was determined by the treating physician based on the clinical condition of the patient. Dosing adjustments were made according to the following weight bands: patients weighing &#8804;60&#8197;kg received 1000&#8197;mg of azithromycin; those weighing 60&#8211;70&#8197;kg received 1250&#8197;mg; while those weighing &#8805;70&#8197;kg received 1500&#8197;mg.</p><p>Five serial blood samples were collected on Day 2 after the start of oral or IV azithromycin at intervals of 30&#8197;min before the azithromycin dose (trough), and at 2, 5, 12 and 24&#8197;h after the azithromycin dose. Blood samples were collected using K<sub>2</sub>EDTA-coated blood collection tubes. Plasma was separated immediately and stored at &#8722;80&#176;C until analysis. Plasma concentrations of azithromycin were estimated using a validated LC-MS/MS assay. To 100&#8197;&#181;L of patient plasma, 25&#8197;&#181;L of roxithromycin (internal standard) and 200&#8197;&#181;L of 5% ammonium hydroxide (NH<sub>4</sub>OH) were added. They were vortex mixed for 1&#8197;min and subsequently 1.5&#8197;mL of ethyl acetate was added. The mixture was centrifuged at 13&#8202;000&#8197;rpm for 5&#8197;min and 1400&#8197;&#181;L of supernatant was evaporated and reconstituted with 200&#8197;&#181;L of 30% methanol. Ten microlitres of the extracted solution was injected into the UPLC system and the analytes were separated using a Luna 5&#8197;&#181;m PFP column of diameter 50&#8202;&#215;&#8202;2.0&#8197;mm. The standards and internal quality controls were prepared from pooled human plasma samples. The calibration curve was linear and was in the range of 0.01&#8211;2&#8197;mg/L. The low, medium and high quality controls were 0.04, 0.5 and 1.5&#8197;mg/L, respectively.</p><p>Multiple reaction monitoring (MRM) of the ions, 749.6&#8202;&#8594;&#8202;158.4 and 837.7&#8202;&#8594;&#8202;158.3 for azithromycin and roxithromycin, respectively, were used for quantification. Non-compartmental analysis was performed by manual curve stripping. AUC was determined using the trapezoid method. The study outcomes assessed were fever clearance time (FCT), clinical cure, clinical failure, microbiological failure, relapse, complications and PK parameters of azithromycin. Follow-up blood cultures were done after completion of 7&#8197;days of antibiotic therapy.</p><sec id="dlaf015-s2.1"><title>Definitions</title><p>
<italic toggle="yes">C</italic>
<sub>max</sub> was defined as the maximum (or peak) serum concentration that azithromycin achieved in plasma after it was administered and before the administration of a second dose.<sup><xref rid="dlaf015-B26" ref-type="bibr">26</xref></sup></p><p>MIC was defined as the lowest concentration of an antibacterial agent which, under strictly controlled <italic toggle="yes">in vitro</italic> conditions, completely prevented visible growth of the test strain of an organism.<sup><xref rid="dlaf015-B27" ref-type="bibr">27</xref></sup> MIC was determined for all <italic toggle="yes">S.</italic> Typhi and <italic toggle="yes">S.</italic> Paratyphi isolates by means of ETEST.</p><p>AUC<sub>24</sub>/MIC was defined as the AUC over 24&#8197;h divided by the MIC.<sup><xref rid="dlaf015-B26" ref-type="bibr">26</xref></sup></p><p>FCT was defined as from the start of appropriate antibiotic therapy to the first instance when the oral temperature dropped below 37.5&#176;C and remained below this level continuously for 48&#8197;h.</p><p>Clinical cure was defined as complete and sustained resolution of fever and other clinical symptoms and signs. Clinical failure was defined as the persistence of fever for &gt;6&#8197;days.</p><p>Microbiological failure was defined as isolation of <italic toggle="yes">S.</italic> Typhi or <italic toggle="yes">S.</italic>&#160;Paratyphi from blood or bone marrow cultures in patients who had been on treatment for enteric fever for &gt;7&#8197;days. Relapse was defined as recurrence of clinical symptoms and signs compatible with enteric fever within 6&#8197;weeks after completion of a course of antibiotics for this disease, after having had complete resolution of symptoms and signs during the same treatment episode.</p></sec></sec><sec sec-type="results" id="dlaf015-s3"><title>Results</title><p>In our study, 25 cases with blood culture-positive uncomplicated enteric fever were included. <italic toggle="yes">S.</italic> Typhi accounted for 92% (<italic toggle="yes">n</italic>&#8202;=&#8202;23) of&#160;cases while 2 (8%) cases had <italic toggle="yes">S.</italic> Paratyphi. The median (IQR,&#160;range) duration of illness was 10 (5&#8211;21, 2&#8211;45)&#8197;days. Azithromycin therapy was started within 24&#8211;48&#8197;h after the blood culture flagged positive for enteric fever. Ten (40%) patients received IV azithromycin while 15 (60%) received oral therapy only. The median (IQR, range) dose of azithromycin that patients received was 1000&#8197;mg (1000&#8211;1250, 1000&#8211;1500)&#8197;mg. Five (20%) patients received active therapy prior to azithromycin monotherapy for a median (IQR, range) duration of 3 (2&#8211;3, 2&#8211;4)&#8197;days. Three (12%) patients received ceftriaxone and 2 (8%) patients received co-trimoxazole as prior active therapy, all of which were susceptible <italic toggle="yes">in vitro</italic> (Table&#160;<xref rid="dlaf015-T1" ref-type="table">1</xref>). Median (IQR, range) MIC of azithromycin was 4 (4&#8211;6, 3&#8211;12)&#8197;mg/L (Table&#160;<xref rid="dlaf015-T1" ref-type="table">1</xref>). For <italic toggle="yes">S</italic>. Typhi, the azithromycin MIC ranged from 3 to 8&#8197;mg/L, with the MIC<sub>50</sub> and MIC<sub>90</sub> at 4 and 8&#8197;mg/L, respectively. In contrast, the azithromycin MICs for the two <italic toggle="yes">S</italic>. Paratyphi isolates were 6 and 12&#8197;mg/L.</p><table-wrap position="float" id="dlaf015-T1" orientation="portrait"><label>Table&#160;1.</label><caption><p>Demographic, clinical and microbiological characteristics of patients with uncomplicated enteric fever treated with azithromycin</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Values (<italic toggle="yes">N</italic>&#8202;=&#8202;25)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years), median (range)</td><td rowspan="1" colspan="1">24 (15&#8211;56)</td></tr><tr><td rowspan="1" colspan="1">Male sex, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">15 (60.0)</td></tr><tr><td rowspan="1" colspan="1">Patients from urban area, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">22 (88.0)</td></tr><tr><td rowspan="1" colspan="1">Days of illness, median (IQR)</td><td rowspan="1" colspan="1">10 (5&#8211;21.0)</td></tr><tr><td rowspan="1" colspan="1">Diarrhoea, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">14 (56.0)</td></tr><tr><td rowspan="1" colspan="1">Vomiting, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">10 (40.0)</td></tr><tr><td rowspan="1" colspan="1">Abdominal pain, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">7 (28.0)</td></tr><tr><td rowspan="1" colspan="1">Admission temp (&#176;C), median (range)</td><td rowspan="1" colspan="1">102.5 (100&#8211;105)</td></tr><tr><td rowspan="1" colspan="1">Hepatomegaly, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">3 (12.0)</td></tr><tr><td rowspan="1" colspan="1">Splenomegaly, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">5 (20.0)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">S</italic>. Typhi, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">23 (92.0)</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">S</italic>. Paratyphi A, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td rowspan="1" colspan="1">MDR<sup><xref rid="tblfn1" ref-type="table-fn">a</xref></sup> isolate, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td rowspan="1" colspan="1">Ciprofloxacin intermediate, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">23 (92.0)</td></tr><tr><td rowspan="1" colspan="1">Chloramphenicol susceptible, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">24 (96.0)</td></tr><tr><td rowspan="1" colspan="1">Co-trimoxazole susceptible, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">24 (96.0)</td></tr><tr><td rowspan="1" colspan="1">Ceftriaxone susceptible, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">25 (100.0)</td></tr><tr><td rowspan="1" colspan="1">Azithromycin susceptible, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">25 (100.0)</td></tr><tr><td rowspan="1" colspan="1">Azithromycin MIC (mg/L), median (IQR, range)</td><td rowspan="1" colspan="1">4 (4&#8211;6, 3&#8211;12)</td></tr><tr><td rowspan="1" colspan="1">Azithromycin dose (mg), median (IQR, range)</td><td rowspan="1" colspan="1">1000 (1000&#8211;1250, 1000&#8211;1500)</td></tr><tr><td rowspan="1" colspan="1">LOS (days), median (IQR, range)</td><td rowspan="1" colspan="1">7 (5.5&#8211;12, 4&#8211;16)</td></tr><tr><td rowspan="1" colspan="1">Fever clearance time, FCT (days), median (IQR, range)</td><td rowspan="1" colspan="1">3 (2&#8211;3, 2&#8211;5)</td></tr><tr><td rowspan="1" colspan="1">Clinical failure, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1">Microbiological failure, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">0 (0)</td></tr><tr><td rowspan="1" colspan="1">Complicated disease, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td rowspan="1" colspan="1">Relapse, <italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>
<sup>a</sup>MDR, resistant to chloramphenicol, ampicillin and co-trimoxazole.</p></fn></table-wrap-foot></table-wrap><p>The median (IQR, range) FCT was 3 (2&#8211;3, 2&#8211;5)&#8197;days, and the median (IQR, range) length of hospital stay (LOS) was 7 (5.5&#8211;12, 4&#8211;16) days. Four (16%) patients developed complications; two (8%) patients developed encephalopathy and two (8%) patients had gastrointestinal bleeding. Treatment was successful in all 25 patients, with no clinical or microbiological failure, relapse or disease-related mortality (Table&#160;<xref rid="dlaf015-T1" ref-type="table">1</xref>).</p><sec id="dlaf015-s3.1"><title>PK of azithromycin in typhoid fever</title><p>The azithromycin plasma concentration levels over a 24&#8197;h time period are displayed in Figure&#160;<xref rid="dlaf015-F1" ref-type="fig">1</xref>. The mean (&#177;SD) azithromycin plasma concentration ranges during the specified sampling times were as follows: trough, 0.24&#8202;&#177;&#8202;0.19&#8197;mg/L; 2&#8197;h after azithromycin, 1.24&#8202;&#177;&#8202;0.98&#8197;mg/L; 5&#8197;h, 0.64&#8202;&#177;&#8202;0.51&#8197;mg/L; 12&#8197;h, 0.31&#8202;&#177;&#8202;0.16&#8197;mg/L; and 24&#8197;h, 0.37&#8202;&#177;&#8202;0.30&#8197;mg/L.</p><fig position="float" id="dlaf015-F1" fig-type="figure" orientation="portrait"><label>Figure&#160;1.</label><caption><p>Azithromycin plasma concentration levels over 24&#8197;h time period.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dlaf015f1.jpg"><alt-text>Azithromycin plasma concentration levels over 24&#8197;h time period.</alt-text></graphic></fig><p>The mean <italic toggle="yes">C</italic><sub>max</sub> attained by azithromycin was 1.38&#8197;mg/L. One patient had a trough plasma concentration below the level of detection and the maximum concentration attained was 3.64&#8197;mg/L. Azithromycin mean half-life was 28.2&#8197;h. The mean plasma <italic toggle="yes">C</italic><sub>max</sub>/MIC and AUC<sub>24</sub>/MIC for azithromycin were 0.29&#8202;&#177;&#8202;0.22 and 2.64&#8202;+&#8202;1.64, respectively (Table&#160;<xref rid="dlaf015-T2" ref-type="table">2</xref>). There was poor inverse correlation (Pearson&#8217;s product moment correlation&#8202;=&#8202;&#8722;0.2) between plasma AUC<sub>24</sub>/MIC ratio and fever clearance (<italic toggle="yes">P</italic>&#8202;=&#8202;0.32; 95% CI, &#8722;0.44 to 0.15) (Figure&#160;<xref rid="dlaf015-F2" ref-type="fig">2</xref>).</p><fig position="float" id="dlaf015-F2" fig-type="figure" orientation="portrait"><label>Figure&#160;2.</label><caption><p>Correlation between azithromycin PK/PD parameters and FCT.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="dlaf015f2.jpg"><alt-text>Correlation between azithromycin PK/PD parameters and FCT.</alt-text></graphic></fig><table-wrap position="float" id="dlaf015-T2" orientation="portrait"><label>Table&#160;2.</label><caption><p>PK parameters of azithromycin</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">&#160;</th><th rowspan="1" colspan="1">&#160;</th><th rowspan="1" colspan="1">&#160;</th><th colspan="2" rowspan="1">Range</th></tr><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Mean&#8202;&#177;&#8202;SD</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Min</th><th align="center" rowspan="1" colspan="1">Max</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AUC<sub>24</sub> (mg&#183;h/L)</td><td rowspan="1" colspan="1">12.08&#8202;&#177;&#8202;6.00</td><td rowspan="1" colspan="1">11.5</td><td rowspan="1" colspan="1">2.84</td><td rowspan="1" colspan="1">24.11</td></tr><tr><td rowspan="1" colspan="1">MIC (mg/L)</td><td rowspan="1" colspan="1">5.24&#8202;&#177;&#8202;2.01</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">12</td></tr><tr><td rowspan="1" colspan="1">AUC<sub>24</sub>/MIC</td><td rowspan="1" colspan="1">2.64&#8202;&#177;&#8202;1.64</td><td rowspan="1" colspan="1">2.19</td><td rowspan="1" colspan="1">0.30</td><td rowspan="1" colspan="1">6.38</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (mg/L)</td><td rowspan="1" colspan="1">1.38&#8202;&#177;&#8202;0.96</td><td rowspan="1" colspan="1">1.28</td><td rowspan="1" colspan="1">0.19</td><td rowspan="1" colspan="1">3.64</td></tr><tr><td rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub>/MIC</td><td rowspan="1" colspan="1">0.29&#8202;&#177;&#8202;0.22</td><td rowspan="1" colspan="1">0.21</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.91</td></tr><tr><td rowspan="1" colspan="1">Elimination rate constant (h<sup>&#8722;1)</sup></td><td rowspan="1" colspan="1">0.04&#8202;&#177;&#8202;0.02</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.07</td></tr><tr><td rowspan="1" colspan="1">Half-life (h)</td><td rowspan="1" colspan="1">28.19&#8202;&#177;&#8202;27.74</td><td rowspan="1" colspan="1">17.22</td><td rowspan="1" colspan="1">9.92</td><td rowspan="1" colspan="1">120.94</td></tr><tr><td rowspan="1" colspan="1">Volume of distribution at terminal phase (L)</td><td rowspan="1" colspan="1">1625.88&#8202;&#177;&#8202;958.04</td><td rowspan="1" colspan="1">1337.53</td><td rowspan="1" colspan="1">653.02</td><td rowspan="1" colspan="1">4131.21</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="dlaf015-s4"><title>Discussion</title><p>Azithromycin is the drug of choice for uncomplicated enteric fever, especially in areas where MDR (resistance to ampicillin, chloramphenicol and co-trimoxazole), XDR (MDR&#8202;+&#8202;fluoroquinolone non-susceptible and ceftriaxone resistant) and fluoroquinolone-resistant <italic toggle="yes">S.</italic> Typhi infections are prevalent.<sup><xref rid="dlaf015-B28" ref-type="bibr">28</xref>,<xref rid="dlaf015-B29" ref-type="bibr">29</xref></sup> The azithromycin MICs for <italic toggle="yes">S.</italic> Typhi are usually in the range 0.25&#8211;16&#8197;mg/L.<sup><xref rid="dlaf015-B30" ref-type="bibr">30&#8211;34</xref></sup> In our study, all of the isolates had azithromycin MICs ranging from 3 to 12&#8197;mg/L. MIC values were higher for <italic toggle="yes">S.</italic> Paratyphi than <italic toggle="yes">S.</italic> Typhi, as observed in other studies from India<sup><xref rid="dlaf015-B35" ref-type="bibr">35</xref></sup> and other parts of the world.<sup><xref rid="dlaf015-B1" ref-type="bibr">1</xref></sup></p><p>There is scarce PK/PD data on azithromycin in enteric fever. Serum levels of azithromycin after oral administration are usually 0.04&#8211;0.4&#8197;mg/L.<sup><xref rid="dlaf015-B10" ref-type="bibr">10</xref></sup> The mean azithromycin plasma concentration levels in our study were lower than the MIC. The dosing used in our study was based on the original article comparing gatifloxacin and azithromycin, which used 20&#8197;mg/kg as the standard dose.<sup><xref rid="dlaf015-B25" ref-type="bibr">25</xref></sup> This is different from the dosing strategies followed elsewhere in the world where a lower dose is used based on a very small paediatric trial done prior to the MDR enteric fever era.<sup><xref rid="dlaf015-B36" ref-type="bibr">36</xref>,<xref rid="dlaf015-B37" ref-type="bibr">37</xref></sup> We followed weight-based dosing, and adjustments were made for oral therapy received by 60% of the study population, which may have resulted in a dose marginally less than 20&#8197;mg/kg IV daily. This may have contributed to a lower plasma concentration, rather than a level &gt;4 times the MIC usually expected for therapeutic efficacy.<sup><xref rid="dlaf015-B26" ref-type="bibr">26</xref>,<xref rid="dlaf015-B38" ref-type="bibr">38</xref></sup> We noted only a marginally higher mean 24&#8197;h azithromycin concentration compared with trough, suggesting that azithromycin did not achieve a steady state by Day 2 of azithromycin treatment. Azithromycin has a slow elimination rate, resulting in longer plasma half-life of up to 70&#8197;h, with a steady state achieved at 14&#8197;days and increased concentrations in tissues, which may be the reason that we were unable to demonstrate this.<sup><xref rid="dlaf015-B39" ref-type="bibr">39&#8211;41</xref></sup></p><p>The mean plasma concentration for azithromycin was low, with low <italic toggle="yes">C</italic><sub>max</sub>/MIC and AUC/MIC ratios. Hence, the measurable plasma concentration of azithromycin that clears typhoid fever remains unknown. Published data indicate that <italic toggle="yes">C</italic><sub>max</sub>/MIC ratios exceeding 8 and an AUC<sub>24</sub>/MIC value of &gt;100 are required for successful treatment and prevention of the emergence of resistance in Gram-negative bacterial infections, but this has not been established for macrolides.<sup><xref rid="dlaf015-B42" ref-type="bibr">42</xref></sup> Macrolide efficacy is determined by the duration of drug concentration above the MIC, and free serum drug levels above the MIC for at least 40%&#8211;50% of the dosing interval.<sup><xref rid="dlaf015-B43" ref-type="bibr">43</xref>,<xref rid="dlaf015-B44" ref-type="bibr">44</xref></sup> However, this has been demonstrated only in the treatment of pneumococcal infections, where the azithromycin AUC<sub>24</sub>/MIC ratio was in the range of 25&#8211;35.<sup><xref rid="dlaf015-B42" ref-type="bibr">42</xref></sup></p><p>In our study there were no clinical or microbiological failures, relapses or disease-related mortality. The median (IQR, range) FCT was 3 (2&#8211;3, 2&#8211;5)&#8197;days, and the median (IQR, range) LOS was 7 (5.5&#8211;12, 4&#8211;16)&#8197;days. At present, even for antibiotics concentrating intracellularly, we continue to use AUC/MIC as a surrogate PK/PD parameter for efficacy; however, whether this is optimal remains unclear. <italic toggle="yes">In vivo</italic> studies for tigecycline reveal that despite low plasma levels, high concentration in PMNLs occurs.<sup><xref rid="dlaf015-B45" ref-type="bibr">45</xref></sup> Similar PK/PD assessments for other antimicrobials have shown that even though free-drug exposure in the plasma is below the MIC, <italic toggle="yes">f</italic>AUC/MIC may be a PD parameter that correlates with efficacy, e.g. tigecycline against both <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Klebsiella pneumoniae</italic>.<sup><xref rid="dlaf015-B46" ref-type="bibr">46</xref></sup> We were unable to measure intracellular concentrations of azithromycin and we were unable to categorically demonstrate if <italic toggle="yes">f</italic>AUC/MIC correlated with efficacy. The extracellular bacteraemia in enteric fever contributing to symptoms in patients<sup><xref rid="dlaf015-B33" ref-type="bibr">33</xref></sup> seems to be effectively controlled by azithromycin, suggesting that antimicrobial benefits probably occur in the extracellular milieu despite low demonstrable plasma levels.</p><p>The low plasma levels of azithromycin, coupled with sporadic reports of azithromycin resistance globally are a cause for concern. Genomic epidemiology studies<sup><xref rid="dlaf015-B47" ref-type="bibr">47</xref></sup> have shown independent acquisition of plasmids and homoplastic mutations conferring antimicrobial resistance occurring repeatedly in multiple lineages of <italic toggle="yes">S.</italic> Typhi, predominantly arising in South Asia before spreading to other regions. Azithromycin resistance mutations are detected at low prevalence in Southeast Asia, with sequenced isolates containing a mutation exclusively in <italic toggle="yes">acrB</italic>, a gene encoding a component of the AcrAB efflux pump (Table&#160;<xref rid="dlaf015-T3" ref-type="table">3</xref>).<sup><xref rid="dlaf015-B23" ref-type="bibr">23</xref>,<xref rid="dlaf015-B48" ref-type="bibr">48&#8211;52</xref></sup></p><table-wrap position="float" id="dlaf015-T3" orientation="portrait"><label>Table&#160;3.</label><caption><p>Azithromycin resistance mechanisms in <italic toggle="yes">S.</italic> Typhi and <italic toggle="yes">S.</italic> Paratyphi A seen in the <italic toggle="yes">acrB</italic> gene in Southeast Asia</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene mutation</th><th align="center" rowspan="1" colspan="1">MIC (mg/L)</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">R717Q/L</td><td rowspan="1" colspan="1">32&#8211;64</td><td rowspan="1" colspan="1">Bangladesh</td><td rowspan="1" colspan="1">Hooda <italic toggle="yes">et al</italic>.<sup><xref rid="dlaf015-B37" ref-type="bibr">37</xref></sup></td></tr><tr><td rowspan="1" colspan="1">R717L</td><td rowspan="1" colspan="1">&gt;256</td><td rowspan="1" colspan="1">Nepal</td><td rowspan="1" colspan="1">Duy <italic toggle="yes">et al</italic>.<sup><xref rid="dlaf015-B35" ref-type="bibr">35</xref></sup></td></tr><tr><td rowspan="1" colspan="1">R717Q</td><td rowspan="1" colspan="1">&gt;16</td><td rowspan="1" colspan="1">India</td><td rowspan="1" colspan="1">Carey <italic toggle="yes">et al</italic>.<sup><xref rid="dlaf015-B22" ref-type="bibr">22</xref></sup></td></tr><tr><td rowspan="1" colspan="1">R717Q</td><td rowspan="1" colspan="1">12 (increasing MIC range)</td><td rowspan="1" colspan="1">Pakistan</td><td rowspan="1" colspan="1">Iqbal <italic toggle="yes">et al</italic>.<sup><xref rid="dlaf015-B34" ref-type="bibr">34</xref></sup></td></tr><tr><td rowspan="1" colspan="1">R717Q/L</td><td rowspan="1" colspan="1">R717Q: 32; R717L: 16</td><td rowspan="1" colspan="1">Singapore</td><td rowspan="1" colspan="1">Octavia <italic toggle="yes">et al</italic>.<sup><xref rid="dlaf015-B36" ref-type="bibr">36</xref></sup></td></tr></tbody></table></table-wrap><p>In our study, we noted a number of limitations. Five (20%) study patients received active therapy prior to azithromycin monotherapy for a median (IQR, range) duration of 3 (2&#8211;3, 2&#8211;4)&#8197;days and this may have marginally affected the measured clinical outcomes. An inverse relationship between azithromycin AUC/MIC and fever clearance was observed, i.e. a high <italic toggle="yes">C</italic><sub>max</sub> and AUC<sub>24</sub>/MIC correlated with shorter time to fever clearance (Figure&#160;<xref rid="dlaf015-F2" ref-type="fig">2</xref>); this was not statistically significant, probably due to small sample size and estimation of azithromycin concentrations performed early in the treatment period for a drug with a long half-life and wide tissue distribution. The MIC cut-offs for our study were determined using the ETEST, and it is well known that the elution of the antibiotic from the gradient strip may lead to double zones and trailing edges, which can result in variability of interpretation.<sup><xref rid="dlaf015-B53" ref-type="bibr">53</xref></sup> This could have also influenced the values of azithromycin AUC<sub>24</sub>/MIC and <italic toggle="yes">C</italic><sub>max</sub>/MIC. Another limitation of our study is that all <italic toggle="yes">S.</italic> Typhi isolates were susceptible (i.e. MIC&#8202;&lt;&#8202;16&#8197;mg/L), hence, it is unclear if outcomes would have differed with resistant isolates. Fifteen patients in our study received oral azithromycin and 10 received an IV formulation; however, there was no demonstrable difference in plasma levels. Literature reveals that due to its stability at low pH, azithromycin has an oral bioavailability of 37%,<sup><xref rid="dlaf015-B54" ref-type="bibr">54</xref></sup> with low peak plasma concentrations.</p><p>Overall, it was heartening to note that despite relatively low concentrations of azithromycin extracellularly, we were unable to demonstrate clinical or microbiological failure.</p><p>To conclude, azithromycin was effective in treating patients with susceptible enteric fever infections. The extracellular azithromycin plasma levels were lower than the MIC, but there were no treatment failures. Further larger clinical trials are needed to correlate intracellular azithromycin concentrations with therapeutic efficacy and establish optimal azithromycin plasma level as a determinant of clinical outcomes in typhoid fever. The traditional paradigm of achieving plasma concentration of an antibiotic at least four times the MIC for the infecting isolate seems flawed when considering antibiotics concentrating intracellularly, as was seen here with azithromycin.</p></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>We would like to acknowledge the patients who generously contributed their time and willingness to be part of this study. We would also like to acknowledge the Department of General Medicine who contributed most of the patients to this study.</p></ack><sec id="dlaf015-s5"><title>Funding</title><p>Funding for this project was received from Institutional Internal Fluid research grant 22Q257, Christian Medical college, Vellore.</p></sec><sec id="dlaf015-s6"><title>Transparency declarations</title><p>No authors declared a conflict of interest.</p></sec><ref-list id="ref1"><title>References</title><ref id="dlaf015-B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hassing</surname> &#160;<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Goessens</surname> &#160;<given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>van Pelt</surname> &#160;<given-names>W</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Salmonella subtypes with increased MICs for azithromycin in travelers returned to The Netherlands</article-title>. <source>Emerg Infect Dis</source> &#160;<year>2014</year>; <volume>20</volume>: <fpage>705</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3201/eid2004.131536</pub-id><pub-id pub-id-type="pmid">24655478</pub-id><pub-id pub-id-type="pmcid">PMC3966360</pub-id></mixed-citation></ref><ref id="dlaf015-B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rupali</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname> &#160;<given-names>OC</given-names></string-name>, <string-name name-style="western"><surname>Jesudason</surname> &#160;<given-names>MV</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Treatment failure in typhoid fever with ciprofloxacin susceptible <italic toggle="yes">Salmonella enterica</italic> serotype Typhi</article-title>. <source>Diagn Microbiol Infect Dis</source> &#160;<year>2004</year>; <volume>49</volume>: <fpage>1</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2003.12.002</pub-id><pub-id pub-id-type="pmid">15135492</pub-id></mixed-citation></ref><ref id="dlaf015-B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bandyopadhyay</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Balaji</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Yadav</surname> &#160;<given-names>B</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Effectiveness of treatment regimens for typhoid fever in the nalidixic acid-resistant <italic toggle="yes">S. typhi</italic> (NARST) era in south India</article-title>. <source>Trop Doct</source> &#160;<year>2018</year>; <volume>48</volume>: <fpage>182</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/0049475518758884</pub-id><pub-id pub-id-type="pmid">29495943</pub-id></mixed-citation></ref><ref id="dlaf015-B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Al Naiemi</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zwart</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rijnsburger</surname> &#160;<given-names>MC</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Extended-spectrum-beta-lactamase production in a <italic toggle="yes">Salmonella enterica</italic> serotype Typhi strain from the Philippines</article-title>. <source>J Clin Microbiol</source> &#160;<year>2008</year>; <volume>46</volume>: <fpage>2794</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00676-08</pub-id><pub-id pub-id-type="pmid">18550740</pub-id><pub-id pub-id-type="pmcid">PMC2519485</pub-id></mixed-citation></ref><ref id="dlaf015-B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Akinyemi</surname> &#160;<given-names>KO</given-names></string-name>, <string-name name-style="western"><surname>Iwalokun</surname> &#160;<given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Alafe</surname> &#160;<given-names>OO</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title><italic toggle="yes">bla</italic><sub>CTX-M-I</sub> group extended spectrum beta-lactamase-producing <italic toggle="yes">Salmonella typhi</italic> from hospitalized patients in Lagos, Nigeria</article-title>. <source>Infect Drug Resist</source> &#160;<year>2015</year>; <volume>8</volume>: <fpage>99</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.2147/IDR.S78876</pub-id><pub-id pub-id-type="pmid">25999745</pub-id><pub-id pub-id-type="pmcid">PMC4437039</pub-id></mixed-citation></ref><ref id="dlaf015-B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Effa</surname> &#160;<given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Bukirwa</surname> &#160;<given-names>H</given-names></string-name></person-group>. <article-title>Azithromycin for treating uncomplicated typhoid and paratyphoid fever (enteric fever)</article-title>. <source>Cochrane Database Syst Rev</source> &#160;<year>2008</year>; issue <issue>4</issue>: <fpage>CD006083</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD006083.pub2</pub-id><pub-id pub-id-type="pmid">18843701</pub-id></mixed-citation></ref><ref id="dlaf015-B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ballow</surname> &#160;<given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Amsden</surname> &#160;<given-names>GW</given-names></string-name></person-group>. <article-title>Azithromycin: the first azalide antibiotic</article-title>. <source>Ann Pharmacother</source> &#160;<year>1992</year>; <volume>26</volume>: <fpage>1253</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1177/106002809202601014</pub-id><pub-id pub-id-type="pmid">1330097</pub-id></mixed-citation></ref><ref id="dlaf015-B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Allaudeen</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chandra</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>2007</year>; <volume>51</volume>: <fpage>103</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00852-06</pub-id><pub-id pub-id-type="pmid">17060516</pub-id><pub-id pub-id-type="pmcid">PMC1797671</pub-id></mixed-citation></ref><ref id="dlaf015-B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Panteix</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guillaumond</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Harf</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>In-vitro concentration of azithromycin in human phagocytic cells</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>1993</year>; <volume>31</volume> &#160;<issue>Suppl E</issue>: <fpage>1</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1093/jac/31.suppl_E.1</pub-id><pub-id pub-id-type="pmid">8396080</pub-id></mixed-citation></ref><ref id="dlaf015-B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Foulds</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Shepard</surname> &#160;<given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>RB</given-names></string-name></person-group>. <article-title>The pharmacokinetics of azithromycin in human serum and tissues</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>1990</year>; <volume>25</volume> &#160;<issue>Suppl A</issue>: <fpage>73</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1093/jac/25.suppl_A.73</pub-id><pub-id pub-id-type="pmid">2154441</pub-id></mixed-citation></ref><ref id="dlaf015-B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rakita</surname> &#160;<given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Jacques-Palaz</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname> &#160;<given-names>BE</given-names></string-name></person-group>. <article-title>Intracellular activity of azithromycin against bacterial enteric pathogens</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>1994</year>; <volume>38</volume>: <fpage>1915</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.38.9.1915</pub-id><pub-id pub-id-type="pmid">7810998</pub-id><pub-id pub-id-type="pmcid">PMC284662</pub-id></mixed-citation></ref><ref id="dlaf015-B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>EUCAST.</collab></person-group> &#160;<source>Breakpoint tables for interpretation of MICs and zone diameters</source>. <year>2014</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf" ext-link-type="uri">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf</ext-link></mixed-citation></ref><ref id="dlaf015-B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parry</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Thieu</surname> &#160;<given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Dolecek</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Clinically and microbiologically derived azithromycin susceptibility breakpoints for <italic toggle="yes">Salmonella enterica</italic> serovars Typhi and Paratyphi A</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>2015</year>; <volume>59</volume>: <fpage>2756</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.04729-14</pub-id><pub-id pub-id-type="pmid">25733500</pub-id><pub-id pub-id-type="pmcid">PMC4394775</pub-id></mixed-citation></ref><ref id="dlaf015-B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Divyashree</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nabarro</surname> &#160;<given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>Veeraraghavan</surname> &#160;<given-names>B</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Enteric fever in India: current scenario and future directions</article-title>. <source>Trop Med Int Health</source> &#160;<year>2016</year>; <volume>21</volume>: <fpage>1255</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1111/tmi.12762</pub-id><pub-id pub-id-type="pmid">27495900</pub-id></mixed-citation></ref><ref id="dlaf015-B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sj&#246;lund-Karlsson</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Joyce</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Blickenstaff</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Antimicrobial susceptibility to azithromycin among <italic toggle="yes">Salmonella enterica</italic> isolates from the United States</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>2011</year>; <volume>55</volume>: <fpage>3985</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00590-11</pub-id><pub-id pub-id-type="pmid">21690279</pub-id><pub-id pub-id-type="pmcid">PMC3165283</pub-id></mixed-citation></ref><ref id="dlaf015-B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname> &#160;<given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Bharti</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pratap</surname> &#160;<given-names>CB</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Drug resistance pattern in the recent isolates of <italic toggle="yes">Salmonella Typhi</italic> with special reference to cephalosporins and azithromycin in the Gangetic Plain</article-title>. <source>J Clin Diagn Res</source> &#160;<year>2017</year>; <volume>11</volume>: <fpage>DM01</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.7860/JCDR/2017/23330.9973</pub-id><pub-id pub-id-type="pmcid">PMC5535361</pub-id><pub-id pub-id-type="pmid">28764168</pub-id></mixed-citation></ref><ref id="dlaf015-B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Manesh</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Balaji</surname> &#160;<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname> &#160;<given-names>DR</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>A case of clinical and microbiological failure of azithromycin therapy in <italic toggle="yes">Salmonella enterica</italic> serotype Typhi despite low azithromycin MIC</article-title>. <source>Int J Infect Dis</source> &#160;<year>2017</year>; <volume>54</volume>: <fpage>62</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2016.11.409</pub-id><pub-id pub-id-type="pmid">27894983</pub-id></mixed-citation></ref><ref id="dlaf015-B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karkey</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Thwaites</surname> &#160;<given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname> &#160;<given-names>S</given-names></string-name></person-group>. <article-title>The evolution of antimicrobial resistance in <italic toggle="yes">Salmonella</italic> Typhi</article-title>. <source>Curr Opin Gastroenterol</source> &#160;<year>2018</year>; <volume>34</volume>: <fpage>25</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1097/MOG.0000000000000406</pub-id><pub-id pub-id-type="pmid">29059070</pub-id></mixed-citation></ref><ref id="dlaf015-B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vlieghe</surname> &#160;<given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Phe</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>De Smet</surname> &#160;<given-names>B</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Azithromycin and ciprofloxacin resistance in <italic toggle="yes">Salmonella</italic> bloodstream infections in Cambodian adults</article-title>. <source>PLoS Negl Trop Dis</source> &#160;<year>2012</year>; <volume>6</volume>: <fpage>e1933</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0001933</pub-id><pub-id pub-id-type="pmid">23272255</pub-id><pub-id pub-id-type="pmcid">PMC3521708</pub-id></mixed-citation></ref><ref id="dlaf015-B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gomes</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mart&#237;nez-Puchol</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Palma</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Macrolide resistance mechanisms in <italic toggle="yes">Enterobacteriaceae</italic>: focus on azithromycin</article-title>. <source>Crit Rev Microbiol</source> &#160;<year>2017</year>; <volume>43</volume>: <fpage>1</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3109/1040841X.2015.1136261</pub-id><pub-id pub-id-type="pmid">27786586</pub-id></mixed-citation></ref><ref id="dlaf015-B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kumari</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dahiya</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Azithromycin resistance mechanisms in typhoidal <italic toggle="yes">Salmonellae</italic> in India: a 25&#8197;years analysis</article-title>. <source>Indian J Med Res</source> &#160;<year>2019</year>; <volume>149</volume>: <fpage>404</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.4103/ijmr.IJMR_1302_17</pub-id><pub-id pub-id-type="pmid">31249207</pub-id><pub-id pub-id-type="pmcid">PMC6607824</pub-id></mixed-citation></ref><ref id="dlaf015-B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><given-names>Tagg</given-names> &#160;<surname>KA</surname></string-name>, <string-name name-style="western"><given-names>Kim</given-names> &#160;<surname>JY</surname></string-name>, <string-name name-style="western"><given-names>Henderson</given-names> &#160;<surname>B</surname></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Azithromycin&#8211;resistant mph(A)&#8211;positive Salmonella enterica serovar Typhi in the United States</article-title>. <source>J Glob Antimicrob Resist</source> &#160;<year>2024</year>; <volume>39</volume>: <fpage>69</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">39173740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jgar.2024.08.005</pub-id><pub-id pub-id-type="pmcid">PMC11663695</pub-id></mixed-citation></ref><ref id="dlaf015-B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carey</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yousuf</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Spontaneous emergence of azithromycin resistance in independent lineages of <italic toggle="yes">Salmonella</italic> Typhi in Northern India</article-title>. <source>Clin Infect Dis</source> &#160;<year>2021</year>; <volume>72</volume>: <fpage>e120</fpage>&#8211;<lpage>e7</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa1773</pub-id><pub-id pub-id-type="pmid">33515460</pub-id><pub-id pub-id-type="pmcid">PMC7935384</pub-id></mixed-citation></ref><ref id="dlaf015-B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rai</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname> &#160;<given-names>KN</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Rationale of azithromycin prescribing practices for enteric fever in India</article-title>. <source>Indian J Med Microbiol</source> &#160;<year>2012</year>; <volume>30</volume>: <fpage>30</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.4103/0255-0857.93017</pub-id><pub-id pub-id-type="pmid">22361757</pub-id></mixed-citation></ref><ref id="dlaf015-B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dolecek</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname> &#160;<given-names>TP</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname> &#160;<given-names>NR</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam</article-title>. <source>PLoS One</source> &#160;<year>2008</year>; <volume>3</volume>: <fpage>e2188</fpage>.<pub-id pub-id-type="pmid">18493312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0002188</pub-id><pub-id pub-id-type="pmcid">PMC2374894</pub-id></mixed-citation></ref><ref id="dlaf015-B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barger</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fuhst</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wiedemann</surname> &#160;<given-names>B</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Pharmacological indices in antibiotic therapy</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>2003</year>; <volume>52</volume>: <fpage>893</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">14613960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkg482</pub-id></mixed-citation></ref><ref id="dlaf015-B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Methods for the determination of susceptibility of bacteria to antimicrobial agents</collab></person-group>. <article-title>Terminology</article-title>. <source>Clin Microbiol Infect</source> &#160;<year>1998</year>; <volume>4</volume>: <fpage>291</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">11864348</pub-id></mixed-citation></ref><ref id="dlaf015-B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Parry</surname> &#160;<given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname> &#160;<given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Phuong Le</surname> &#160;<given-names>T</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>2007</year>; <volume>51</volume>: <fpage>819</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00447-06</pub-id><pub-id pub-id-type="pmid">17145784</pub-id><pub-id pub-id-type="pmcid">PMC1803150</pub-id></mixed-citation></ref><ref id="dlaf015-B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crump</surname> &#160;<given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Sj&#246;lund-Karlsson</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gordon</surname> &#160;<given-names>MA</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive <italic toggle="yes">Salmonella</italic> infections</article-title>. <source>Clin Microbiol Rev</source> &#160;<year>2015</year>; <volume>28</volume>: <fpage>901</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00002-15</pub-id><pub-id pub-id-type="pmid">26180063</pub-id><pub-id pub-id-type="pmcid">PMC4503790</pub-id></mixed-citation></ref><ref id="dlaf015-B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Metchock</surname> &#160;<given-names>B</given-names></string-name></person-group>. <article-title>In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against <italic toggle="yes">Salmonella typhi</italic></article-title>. <source>J Antimicrob Chemother</source> &#160;<year>1990</year>; <volume>25</volume> &#160;<issue>Suppl A</issue>: <fpage>29</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1093/jac/25.suppl_A.29</pub-id><pub-id pub-id-type="pmid">2154435</pub-id></mixed-citation></ref><ref id="dlaf015-B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gordillo</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname> &#160;<given-names>KV</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname> &#160;<given-names>BE</given-names></string-name></person-group>. <article-title>In vitro activity of azithromycin against bacterial enteric pathogens</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>1993</year>; <volume>37</volume>: <fpage>1203</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.37.5.1203</pub-id><pub-id pub-id-type="pmid">8390813</pub-id><pub-id pub-id-type="pmcid">PMC187935</pub-id></mixed-citation></ref><ref id="dlaf015-B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tribble</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Girgis</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Habib</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Efficacy of azithromycin for typhoid fever</article-title>. <source>Clin Infect Dis</source> &#160;<year>1995</year>; <volume>21</volume>: <fpage>1045</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/clinids/21.4.1045</pub-id><pub-id pub-id-type="pmid">8645805</pub-id></mixed-citation></ref><ref id="dlaf015-B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butler</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Frenck</surname> &#160;<given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname> &#160;<given-names>RB</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title><italic toggle="yes">In vitro</italic> effects of azithromycin on <italic toggle="yes">Salmonella typhi</italic>: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>2001</year>; <volume>47</volume>: <fpage>455</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/jac/47.4.455</pub-id><pub-id pub-id-type="pmid">11266420</pub-id></mixed-citation></ref><ref id="dlaf015-B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Butler</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sridhar</surname> &#160;<given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Daga</surname> &#160;<given-names>MK</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>1999</year>; <volume>44</volume>: <fpage>243</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1093/jac/44.2.243</pub-id><pub-id pub-id-type="pmid">10473232</pub-id></mixed-citation></ref><ref id="dlaf015-B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chatterjee</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Eshwara</surname> &#160;<given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Tellapragada</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Azithromycin susceptibility among clinical isolates of <italic toggle="yes">Salmonella</italic>: interfacing guidelines with routine practices</article-title>. <source>Indian J Med Microbiol</source> &#160;<year>2016</year>; <volume>34</volume>: <fpage>397</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4103/0255-0857.188376</pub-id><pub-id pub-id-type="pmid">27514976</pub-id></mixed-citation></ref><ref id="dlaf015-B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frenck</surname> &#160;<given-names>RW</given-names>, <suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Nakhla</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sultan</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children</article-title>. <source>Clin Infect Dis</source> &#160;<year>2000</year>; <volume>31</volume>: <fpage>1134</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11073741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/317450</pub-id></mixed-citation></ref><ref id="dlaf015-B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Frenck</surname> &#160;<given-names>RW</given-names>, <suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Mansour</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nakhla</surname> &#160;<given-names>I</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents</article-title>. <source>Clin Infect Dis</source> &#160;<year>2004</year>; <volume>38</volume>: <fpage>951</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15034826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/382359</pub-id></mixed-citation></ref><ref id="dlaf015-B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ambrose</surname> &#160;<given-names>PG</given-names>, <suffix>Jr.</suffix></string-name>, <string-name name-style="western"><surname>Owens</surname> &#160;<given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Grasela</surname> &#160;<given-names>D</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Antimicrobial pharmacodynamics</article-title>. <source>Med Clin North Am</source> &#160;<year>2000</year>; <volume>84</volume>: <fpage>1431</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">11155851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0025-7125(05)70296-0</pub-id></mixed-citation></ref><ref id="dlaf015-B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Matzneller</surname> &#160;<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zeitlinger</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>2014</year>; <volume>58</volume>: <fpage>6675</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">25155592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.02904-14</pub-id><pub-id pub-id-type="pmcid">PMC4249372</pub-id></mixed-citation></ref><ref id="dlaf015-B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choi</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yim</surname> &#160;<given-names>DS</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life</article-title>. <source>Drug Des Devel Ther</source> &#160;<year>2020</year>; <volume>14</volume>: <fpage>811</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S236701</pub-id><pub-id pub-id-type="pmcid">PMC7049277</pub-id><pub-id pub-id-type="pmid">32158198</pub-id></mixed-citation></ref><ref id="dlaf015-B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zuckerman</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Qamar</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bono</surname> &#160;<given-names>BR</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline)</article-title>. <source>Med Clin North Am</source> &#160;<year>2011</year>; <volume>95</volume>: <fpage>761</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">21679791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2011.03.012</pub-id></mixed-citation></ref><ref id="dlaf015-B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Craig</surname> &#160;<given-names>WA</given-names></string-name></person-group>. <article-title>Does the dose matter?</article-title> &#160;<source>Clin Infect Dis</source> &#160;<year>2001</year>; <volume>33</volume> &#160;<issue>Suppl 3</issue>: <fpage>S233</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1086/321854</pub-id><pub-id pub-id-type="pmid">11524724</pub-id></mixed-citation></ref><ref id="dlaf015-B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rybak</surname> &#160;<given-names>MJ</given-names></string-name></person-group>. <article-title>Pharmacodynamics: relation to antimicrobial resistance</article-title>. <source>Am J Infect Control</source> &#160;<year>2006</year>; <volume>34</volume>(<issue>Suppl 1</issue>): <fpage>S38</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">16813981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajic.2006.05.227</pub-id></mixed-citation></ref><ref id="dlaf015-B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Craig</surname> &#160;<given-names>WA.</given-names></string-name></person-group> &#160;<article-title>Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men</article-title>. <source>Clin Infect Dis</source> &#160;<year>1998</year>; <volume>26</volume>: <fpage>1</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="pmid">9455502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/516284</pub-id></mixed-citation></ref><ref id="dlaf015-B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ong</surname> &#160;<given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Babalola</surname> &#160;<given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Nightingale</surname> &#160;<given-names>CH</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs)</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>2005</year>; <volume>56</volume>: <fpage>498</fpage>&#8211;<lpage>501</lpage>.<pub-id pub-id-type="pmid">16024591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dki260</pub-id></mixed-citation></ref><ref id="dlaf015-B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nicasio</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Crandon</surname> &#160;<given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Nicolau</surname> &#160;<given-names>DP</given-names></string-name></person-group>. In <article-title>vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates</article-title>. <source>Antimicrob Agents Chemother</source> &#160;<year>2009</year>; <volume>53</volume>: <fpage>2756</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">19364850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01678-08</pub-id><pub-id pub-id-type="pmcid">PMC2704680</pub-id></mixed-citation></ref><ref id="dlaf015-B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>da Silva</surname> &#160;<given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Tanmoy</surname> &#160;<given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Pragasam</surname> &#160;<given-names>AK</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>The international and intercontinental spread and expansion of antimicrobial-resistant <italic toggle="yes">Salmonella</italic> Typhi: a genomic epidemiology study</article-title>. <source>Lancet Microbe</source> &#160;<year>2022</year>; <volume>3</volume>: <fpage>e567</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/S2666-5247(22)00093-3</pub-id><pub-id pub-id-type="pmid">35750070</pub-id><pub-id pub-id-type="pmcid">PMC9329132</pub-id></mixed-citation></ref><ref id="dlaf015-B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carey</surname> &#160;<given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Dyson</surname> &#160;<given-names>ZA</given-names></string-name>, <string-name name-style="western"><surname>Ingle</surname> &#160;<given-names>DJ</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Global diversity and antimicrobial resistance of typhoid fever pathogens: insights from a meta-analysis of 13,000 <italic toggle="yes">Salmonella</italic> Typhi genomes</article-title>. <source>Elife</source> &#160;<year>2023</year>; <volume>12</volume>: <fpage>e85867</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.85867</pub-id><pub-id pub-id-type="pmid">37697804</pub-id><pub-id pub-id-type="pmcid">PMC10506625</pub-id></mixed-citation></ref><ref id="dlaf015-B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Iqbal</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dehraj</surname> &#160;<given-names>IF</given-names></string-name>, <string-name name-style="western"><surname>Carey</surname> &#160;<given-names>ME</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>A race against time: reduced azithromycin susceptibility in <italic toggle="yes">Salmonella enterica</italic> serovar Typhi in&#160;Pakistan</article-title>. <source>mSphere</source> &#160;<year>2020</year>; <volume>5</volume>: <fpage>e00215&#8211;20</fpage>. <pub-id pub-id-type="doi">10.1128/msphere.00215-20</pub-id><pub-id pub-id-type="pmid">32699118</pub-id><pub-id pub-id-type="pmcid">PMC7376502</pub-id></mixed-citation></ref><ref id="dlaf015-B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duy</surname> &#160;<given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Dongol</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Giri</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>The emergence of azithromycin-resistant <italic toggle="yes">Salmonella</italic> Typhi in Nepal</article-title>. <source>JAC Antimicrob Resist</source> &#160;<year>2020</year>; <volume>2</volume>: <fpage>dlaa109</fpage>. <pub-id pub-id-type="doi">10.1093/jacamr/dlaa109</pub-id><pub-id pub-id-type="pmid">34223059</pub-id><pub-id pub-id-type="pmcid">PMC8210228</pub-id></mixed-citation></ref><ref id="dlaf015-B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Octavia</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chew</surname> &#160;<given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname> &#160;<given-names>RTP</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Azithromycin-resistant <italic toggle="yes">Salmonella enterica</italic> serovar Typhi AcrB-R717Q/L, Singapore</article-title>. <source>Emerg Infect Dis</source> &#160;<year>2021</year>; <volume>27</volume>: <fpage>624</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3201/eid2702.203874</pub-id><pub-id pub-id-type="pmid">33496224</pub-id><pub-id pub-id-type="pmcid">PMC7853538</pub-id></mixed-citation></ref><ref id="dlaf015-B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hooda</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sajib</surname> &#160;<given-names>MSI</given-names></string-name>, <string-name name-style="western"><surname>Rahman</surname> &#160;<given-names>H</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Molecular mechanism of azithromycin resistance among typhoidal <italic toggle="yes">Salmonella</italic> strains in Bangladesh identified through passive pediatric surveillance</article-title>. <source>PLoS Negl Trop Dis</source> &#160;<year>2019</year>; <volume>13</volume>: <fpage>e0007868</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0007868</pub-id><pub-id pub-id-type="pmid">31730615</pub-id><pub-id pub-id-type="pmcid">PMC6881056</pub-id></mixed-citation></ref><ref id="dlaf015-B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Goldblatt</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yusuf</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>Azithromycin susceptibility testing for Salmonella enterica isolates: discordances in results using MIC gradient strips</article-title>. <source>J Antimicrob Chemother</source> &#160;<year>2020</year>; <volume>75</volume>: <fpage>1820</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="pmid">32221592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkaa097</pub-id></mixed-citation></ref><ref id="dlaf015-B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fohner</surname> &#160;<given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Sparreboom</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname> &#160;<given-names>RB</given-names></string-name> &#160;<etal>et al</etal></person-group> &#160;<article-title>PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics</article-title>. <source>Pharmacogenet Genomics</source> &#160;<year>2017</year>; <volume>27</volume>: <fpage>164</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28146011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0000000000000270</pub-id><pub-id pub-id-type="pmcid">PMC5346035</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>